Asunto(s)
Mutación , Síndromes Mielodisplásicos/genética , Enfermedades Mielodisplásicas-Mieloproliferativas/genética , Trastornos Mieloproliferativos/genética , Proteínas ras/genética , Secuencia de Aminoácidos , Secuencia de Bases , Mapeo Cromosómico , Regulación Leucémica de la Expresión Génica , Humanos , Datos de Secuencia Molecular , Síndromes Mielodisplásicos/mortalidad , Enfermedades Mielodisplásicas-Mieloproliferativas/mortalidad , Trastornos Mieloproliferativos/mortalidad , Proteínas ras/químicaRESUMEN
Polycomb repressive complex 2 (PRC2) is involved in trimethylation of histone H3 lysine 27 (H3K27), chromatin condensation and transcriptional repression. The silencing function of PRC2 complex is mostly attributed to its intrinsic activity for methylating H3K27. Unlike in B-cell lymphomas, enhancer of zeste homolog 2 (EZH2) mutations in myeloid malignancies are inactivating/hypomorphic. When we assessed the mutational status in myeloid malignancies (N=469 cases examined), we found EZH2 and EED/SUZ12 mutations in 8% and 3.3% of cases, respectively. In addition to mutant cases, reduced EZH2 expression was also found in 78% cases with hemizygous deletion (-7/del7q cases involving EZH2 locus) and 41% of cases with diploid chromosome 7, most interestingly cases with spliceosomal mutations (U2AF1/SRSF2 mutations; 63% of cases). EZH2 mutations were characterized by decreased H3K27 trimethylation and increased chromatin relaxation at specific gene loci accompanied by higher transcriptional activity. One of the major downstream target is HOX gene family, involved in the regulation of stem cell self-renewal. HOXA9 was found to be overexpressed in cases with decreased EZH2 expression either by EZH2/spliceosomal mutations or because of -7/del7q. In summary, our results suggest that loss of gene repression through a variety of mutations resulting in reduced H3K27 trimethylation may contribute to leukemogenesis.
Asunto(s)
Epigénesis Genética , Neoplasias Hematológicas/genética , Histonas/genética , Complejo Represivo Polycomb 2/metabolismo , Western Blotting , Cromosomas Humanos Par 7 , Proteína Potenciadora del Homólogo Zeste 2 , Humanos , Mutación , Pronóstico , Reacción en Cadena en Tiempo Real de la PolimerasaAsunto(s)
Proteínas de Unión al ADN/genética , Leucemia Mieloide Aguda/genética , Proteínas Mutantes/genética , Mutación Missense/genética , Síndromes Mielodisplásicos/genética , Trastornos Mieloproliferativos/genética , Factores de Transcripción/genética , Disomía Uniparental/genética , Adulto , Anciano , Anciano de 80 o más Años , Secuencia de Bases , Cromosomas Humanos Par 7/genética , Proteína Potenciadora del Homólogo Zeste 2 , Femenino , Heterocigoto , Homocigoto , Humanos , Leucemia Mieloide Aguda/patología , Pérdida de Heterocigocidad , Masculino , Persona de Mediana Edad , Datos de Secuencia Molecular , Síndromes Mielodisplásicos/patología , Trastornos Mieloproliferativos/patología , Complejo Represivo Polycomb 2 , Polimorfismo de Nucleótido Simple/genética , Eliminación de Secuencia , Homología de Secuencia de Ácido Nucleico , Disomía Uniparental/patologíaAsunto(s)
Janus Quinasa 2/genética , Neutrófilos/metabolismo , Trombocitosis/diagnóstico , Trombocitosis/genética , Trombosis/etiología , Trombosis/genética , Adulto , Anciano , Anciano de 80 o más Años , Alelos , Plaquetas/metabolismo , Femenino , Humanos , Masculino , Persona de Mediana Edad , Factores de Tiempo , Resultado del TratamientoRESUMEN
Idiopathic myelofibrosis (IMF) is a hematopoietic stem cell disorder characterized by hypercellularity of the bone marrow with an increase in abnormal megakaryocytes, varying degrees of marrow fibrosis, and extramedullary hematopoiesis. The central lesion of the IMF stem cell is not known; however, the marrow fibrosis is a polyclonal reaction to inflammatory mediators generated by the transformed clone. Historical management approaches have centered on improving the patient's blood counts in a palliative manner. Recent reports of autologous and allogeneic bone marrow transplantation (BMT) in IMF patients indicate that stable engraftment occurs easily, the marrow fibrosis is a reversible process, and a graft-versus-fibrosis effect may exist. The goals of future therapies will target marrow fibrosis and harness the graft-versus-fibrosis effect to safely and effectively treat patients with IMF.
Asunto(s)
Trasplante de Médula Ósea , Médula Ósea/patología , Trastornos Mieloproliferativos/patología , Mielofibrosis Primaria/terapia , Animales , Humanos , Mielofibrosis Primaria/patología , PronósticoRESUMEN
Recently, we demonstrated a marked reduction in the expression of the thrombopoietin receptor, Mpl, in polycythemia vera (PV) platelets and megakaryocytes using an antiserum against the Mpl extracellular domain. To further examine this abnormality, we raised an antibody to the Mpl C-terminus. Immunologic analysis of PV platelets with this antiserum confirmed the reduction in Mpl expression. However, the C-terminal antiserum detected 2 forms of Mpl in PV platelets in contrast to normal platelets, in which a single form of Mpl was detected by both the extracellular domain and C-terminal antisera. Two-dimensional gel electrophoresis studies with isoelectric focusing in the first dimension identified normal platelet Mpl as an 85 to 92 kD protein with an isoelectric point (pI) of 5.5. PV platelets contained an additional 80 to 82 kD Mpl Mpl isoform with a pI of 6.5. Analysis of Mpl expressed by the human megakaryocytic cell line, Dami, showed 2 isoforms similar to those found in PV platelets suggesting a precursor-product relationship. Digestion of Dami cell and normal platelet lysates with neuraminidase converted the more acidic Mpl isoform to the more basic one, indicating that the 2 isoforms differed with respect to posttranslational glycosylation. Furthermore, in contrast to normal platelet Mpl, PV platelet Mpl was susceptible to endoglycosidase H digestion, indicating defective Mpl processing by PV megakaryocytes. The glycosylation defect was specific for Mpl, as 2 other platelet membrane glycoproteins, glycoprotein IIb and multimerin, were processed normally. Importantly, the extent of the PV platelet Mpl glycosylation defect correlated with disease duration and extramedullary hematopoiesis.
Asunto(s)
Policitemia Vera/metabolismo , Procesamiento Proteico-Postraduccional , Proteínas Proto-Oncogénicas/metabolismo , Receptores de Citocinas , Secuencia de Aminoácidos , Plaquetas/metabolismo , Glicosilación , Humanos , Manosil-Glicoproteína Endo-beta-N-Acetilglucosaminidasa/metabolismo , Megacariocitos/metabolismo , Datos de Secuencia Molecular , Proteínas de Neoplasias/metabolismo , Receptores de Trombopoyetina , Células Tumorales CultivadasRESUMEN
BACKGROUND: The cause of polycythemia vera, which originates from a multipotent hematopoietic progenitor cell, is unknown. Thrombopoietin is a hematopoietic growth factor that regulates the production of multipotent hematopoietic progenitor cells and platelets. To evaluate the possibility that an abnormality in thrombopoietin-mediated signal transduction might be involved in the pathogenesis of polycythemia vera, we examined thrombopoietin-induced tyrosine phosphorylation of proteins and the expression of the thrombopoietin receptor in platelets from patients with the disease. METHODS: Platelets were isolated from the blood of patients with polycythemia vera or other chronic myeloproliferative disorders and control subjects. The platelets were exposed to either thrombopoietin or thrombin and then lysed for analysis of tyrosine phosphorylation of platelet proteins and the expression of the proteins by means of immunoblotting. Expression of the thrombopoietin receptor (Mpl) by platelets and megakaryocytes was also assessed. RESULTS: Thrombopoietin-mediated tyrosine phosphorylation of proteins was impaired in platelets from 20 patients with polycythemia vera and 3 with idiopathic myelofibrosis, but not in 4 patients with essential thrombocytosis, 3 with chronic myelogenous leukemia, 6 with secondary erythrocytosis, 2 with iron-deficiency anemia, 4 with hemochromatosis, or 5 normal subjects. Thrombin-mediated tyrosine phosphorylation of proteins was intact in platelets from patients with polycythemia vera, and the tyrosine kinases and substrates involved in the process were present in normal amounts. However, expression of the platelet thrombopoietin receptor MpI was markedly reduced or absent in 34 of 34 patients with polycythemia vera and in 13 of 14 patients with idiopathic myelofibrosis. Impaired thrombopoietin-induced tyrosine phosphorylation of proteins in patients with these two diseases was uniformly associated with markedly reduced expression of MpI or the lack of its expression. In patients with polycythemia vera, reduced expression of MpI by platelets was associated with reduced expression of MpI by megakaryocytes. CONCLUSIONS: Reduced expression of the thrombopoietin receptor MpI is characteristic of polycythemia vera and idiopathic myelofibrosis. The abnormality appears to distinguish polycythemia vera from other-forms of erythrocytosis.
Asunto(s)
Plaquetas/química , Proteínas de Neoplasias , Policitemia Vera/fisiopatología , Proteínas Proto-Oncogénicas/análisis , Receptores de Citocinas , Adulto , Anciano , Anciano de 80 o más Años , Plaquetas/metabolismo , Femenino , Humanos , Masculino , Megacariocitos/química , Persona de Mediana Edad , Trastornos Mieloproliferativos/sangre , Trastornos Mieloproliferativos/fisiopatología , Fosforilación , Policitemia Vera/sangre , Policitemia Vera/patología , Receptores de Trombopoyetina , Transducción de Señal/efectos de los fármacos , Trombina/farmacología , Trombopoyetina/sangre , Trombopoyetina/farmacología , Tirosina/metabolismoRESUMEN
The pathogenesis of polycythemia vera (PV), a disease involving a multipotent hematopoietic progenitor cell, is unknown. Thrombopoietin (TPO) is a newly characterized hematopoietic growth factor which regulates the production of multipotent hematopoietic progenitor cells as well as platelets. To evaluate the possibility that an abnormality in TPO-mediated signal transduction might be involved in the pathogenesis of PV, we examined TPO-induced protein tyrosine phosphorylation using platelets as a surrogate model system. Platelets were isolated from the blood of patients with PV as well as from patients with other chronic myeloproliferative disorders and control subjects. Impaired TPO-mediated platelet protein tyrosine phosphorylation was a consistent observation in patients with PV as well as those with idiopathic myelofibrosis (IMF), in contrast to patients with essential thrombocytosis, chronic myelogenous leukemia, secondary erythrocytosis, iron deficiency anemia, hemochromatosis, or normal volunteers. Thrombin-mediated platelet protein tyrosine phosphorylation was intact in PV platelets as was expression of the appropriate tyrosine kinases and their cognate substrates. However, expression of the platelet TPO receptor, Mpl, as determined by immunoblotting, chemical crosslinking or flow cytometry was markedly reduced or absent in 34 of 34 PV patients and also in 13 of 14 IMF patients. Impaired TPO-induced protein tyrosine phosphorylation in PV and IMF platelets was uniformly associated with markedly reduced or absent expression of Mpl. We conclude that reduced expression of Mpl is a phenotypic characteristic of platelets from patients with PV and IMF. The abnormality appears to distinguish PV from other forms of erythrocytosis and may be involved in the platelet function defect associated with PV.
Asunto(s)
Plaquetas/metabolismo , Proteínas de Neoplasias , Policitemia Vera/sangre , Policitemia Vera/fisiopatología , Receptores de Citocinas , Transducción de Señal/fisiología , Trombopoyetina/sangre , Plaquetas/patología , Humanos , Janus Quinasa 2 , Fosforilación , Agregación Plaquetaria/efectos de los fármacos , Agregación Plaquetaria/fisiología , Policitemia Vera/etiología , Mielofibrosis Primaria/sangre , Proteínas Tirosina Quinasas/metabolismo , Proteínas/metabolismo , Proteínas Proto-Oncogénicas/metabolismo , Ensayo de Unión Radioligante , Receptores de Trombopoyetina , Tirosina/metabolismoRESUMEN
Cancer patients frequently develop anemia, due either to the cancer itself or to the effects of cancer-related therapy. Recent years have brought insights into both the pathogenesis of the anemia of cancer and the extent to which erythropoietin regulation participates in this process. Although transfusion therapy was the mainstay of therapy for symptomatic anemia in the past, clinical trials have demonstrated that recombinant human erythropoietin can alleviate both anemia and transfusion requirements in many cancer patients and may prove to have an important role in the treatment of cancer-related anemia in the future.